Siga Technologies Inc cash flow statement
In fiscal 2025, Siga Technologies Inc's operations generated $43.5m of cash; it spent $355,009 on capital projects, leaving free cash flow of $43.1m. It returned $43.1m in dividends.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −117 | −18 | 69 | −18 | 72 | 11 | 42 | 95 | 49 | 43 | −20 |
| Depreciation and amortisation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 2 | 4 | 4 | 4 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −117 | −18 | 69 | −18 | 72 | 11 | 42 | 95 | 49 | 43 | −20 |
| Free cash flow after stock pay | −118 | −20 | 66 | −20 | 70 | 10 | 40 | 93 | 45 | 39 | −24 |
| Dividends paid | — | — | — | — | 0 | 0 | 33 | 32 | 43 | 43 | 44 |
| Share buybacks | 0 | 0 | 0 | 0 | 29 | 26 | 13 | 11 | 0 | 0 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | 56 | 7 | 63 | −10 | −17 | −9 | 15 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −7 | 56 | 7 | 63 | −10 | −17 | −9 | 15 |
| Free cash flow after stock pay | −8 | 56 | 6 | 62 | −11 | −18 | −9 | 14 |
Compare with peers
- Tango Therapeutics, Inc. cash flow
- Gossamer Bio, Inc. cash flow
- Nektar Therapeutics cash flow
- Ocular Therapeutix, Inc cash flow
- Invivyd, Inc. cash flow
Head to head: SIGA vs TNGXGOSS vs SIGANKTR vs SIGAOCUL vs SIGA
More: Biotechnology stocks compared, Health Care sector, rankings of US companies